Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13173652 | 0.96 | AKR1C3 (0.73) | AKR1C3KMT2AMEN1RAB9AATM | |
| SCHEMBL13174668 | 0.91 | AKR1C3 (0.74) | AKR1C3KMT2AMEN1RAB9AATM | |
| SCHEMBL13100341 | 0.90 | KMT2A (0.65) | AKR1C3KMT2AMEN1RAB9AATM | |
| SCHEMBL13356146 | 0.89 | AKR1C3 (0.64) | AKR1C3KMT2AMEN1RAB9AATM | |
| SCHEMBL3104370 | 0.88 | AKR1C3 (1.00) | AKR1C3KMT2AMEN1RAB9AHRH4 | |
| SCHEMBL3112510 | 0.88 | AKR1C3 (0.80) | AKR1C3KMT2AMEN1HRH4 | |
| SCHEMBL3095191 | 0.87 | AKR1C3 (0.78) | AKR1C3KMT2AMEN1RAB9AHRH4 | |
| SCHEMBL3106364 | 0.87 | AKR1C3 (0.78) | AKR1C3KMT2AMEN1RAB9AATM | |
| SCHEMBL3089444 | 0.87 | AKR1C3 (0.78) | AKR1C3KMT2AMEN1RAB9AHRH4 | |
| SCHEMBL3106490 | 0.87 | AKR1C3 (0.78) | AKR1C3KMT2AMEN1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | claimed |
| EP-2181990-B1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2012-08-08 | — | — | EP | claimed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | claimed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | claimed |
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513422-B2 | Piperidine derivative | ASTELLAS PHARMA INC. (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2181990-B1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2012-08-08 | — | — | EP | disclosed |
| EP-2181990-B1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2181990-A1 | PIPERIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256189-A1 | PIPERIDINE DERIVATIVE | AR, NR5A1, CYP17A1 | AKR1C3 72/4885KMT2A 1056/4885MEN1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.